Barclays
SPPI

Barclays’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Barclays’s Portfolio SPPI Stock Details SPPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-800
Closed -$3K – 5707
2020
Q2 		$3K Sell
800
-6,400
-89% -$18.6K ﹤0.01% 5435
2020
Q1 		$17K Sell
7,200
-4,900
-40% -$13.4K ﹤0.01% 5695
2019
Q4 		$44K Buy
+12,100
New +$97.8K ﹤0.01% 5772
2019
Q2 		– Sell
-600
Closed -$6K – 7393
2019
Q1 		$6K Sell
600
-7,200
-92% -$77.1K ﹤0.01% 6688
2018
Q4 		$68K Sell
7,800
-90,500
-92% -$1.15M ﹤0.01% 5295
2018
Q3 		$1.65M Buy
98,300
+75,900
+339% +$1.64M ﹤0.01% 3111
2018
Q2 		$469K Buy
22,400
+16,800
+300% +$311K ﹤0.01% 4011
2018
Q1 		$90K Sell
5,600
-1,000
-15% -$19.8K ﹤0.01% 5456
2017
Q4 		$125K Buy
6,600
+2,700
+69% +$48.9K ﹤0.01% 5064
2017
Q3 		$55K Buy
3,900
+2,900
+290% +$26.2K ﹤0.01% 5306
2017
Q2 		$7K Sell
1,000
-7,600
-88% -$49.7K ﹤0.01% 6167
2017
Q1 		$56K Buy
8,600
+2,700
+46% +$15.1K ﹤0.01% 5281
2016
Q4 		$26K Sell
5,900
-3,200
-35% -$13.4K ﹤0.01% 5504
2016
Q3 		$42K Buy
9,100
+1,000
+12% +$5.92K ﹤0.01% 5074
2016
Q2 		$53K Buy
8,100
+7,000
+636% +$49.5K ﹤0.01% 4802
2016
Q1 		$7K Buy
1,100
+1,000
+1,000% +$5.13K ﹤0.01% 5591
2015
Q4 		$1K Sell
100
-11,300
-99% -$64.6K ﹤0.01% 5876
2015
Q3 		$57K Buy
11,400
+5,800
+104% +$40.3K ﹤0.01% 4949
2015
Q2 		$34K Sell
5,600
-20,700
-79% -$131K ﹤0.01% 5386
2015
Q1 		$158K Buy
26,300
+8,000
+44% +$53.2K ﹤0.01% 4522
2014
Q4 		$110K Buy
18,300
+4,200
+30% +$30.9K ﹤0.01% 5130
2014
Q3 		$113K Buy
14,100
+10,300
+271% +$80.6K ﹤0.01% 5227
2014
Q2 		$30K Sell
3,800
-15,500
-80% -$118K ﹤0.01% 6292
2014
Q1 		$135K Buy
19,300
+1,900
+11% +$16.1K ﹤0.01% 5171
2013
Q4 		$139K Buy
17,400
+6,400
+58% +$57.2K ﹤0.01% 5349
2013
Q3 		$88K Sell
11,000
-16,900
-61% -$137K ﹤0.01% 5712
2013
Q2 		$208K Buy
+27,900
New +$214K ﹤0.01% 5140

Other funds holding SPPI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Barclays's SPPI Position: Q2 2022 in Review

Barclays sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q2 2022, closing a stake of 26,470 shares — an estimated $34K sold.

Barclays first reported a position in SPPI in Q2 2013 and held it in 36 quarters. The position peaked at $20.6M in Q4 2017. 86 funds tracked by Wall St. Rank hold SPPI as of Q2 2022.

  • Barclays reported no remaining Spectrum Pharmaceuticals Inc position as of Q2 2022 after selling out during the quarter.
  • Barclays sold 26,470 Spectrum Pharmaceuticals Inc shares in Q2 2022, an estimated $34K.
  • Barclays first reported a position in Spectrum Pharmaceuticals Inc in Q2 2013 and held it in 36 quarters.
  • Barclays's Spectrum Pharmaceuticals Inc position peaked at $20.6M in Q4 2017.
  • 86 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.